ArticleMedicine2025
Causal relationship between the plasma lipidome and urological cancers: A two-sample Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of lipid-lowering drugs in urologic and male reproductive cancers: a Mendelian randomization study.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The plasma lipidome has been found to be closely related to inflammation, obesity, aging, and other diseases, including various cancers. However, the causal relationship between specific plasma lipid species and the risk of urological cancers remains unclear. This study aimed to investigate the causal relationship between 179 lipid species and 3 common types of urological cancers using a two-sample Mendelian randomization (MR) approach. Large-scale genome-wide association study datasets of 179 lipid species were analyzed to evaluate the association between the plasma lipidome and urological cancers, including bladder cancer, kidney cancer, and prostate cancer. The inverse variance weighted method was employed as the primary analysis approach, supplemented by MR-Egger regression, weighted median, weighted mode, and simple mode methods to ensure the reliability of the findings. Sensitivity analyses, including Cochran Q test, MR-Egger intercept test, MR Pleiotropy Residual Sum And Outlier, and leave-one-out analysis, were performed to assess the stability and robustness of the causal relationship. The inverse variance weighted analysis showed that higher levels of sterol ester (SE) (27:1/16:0) and other plasma lipidome were causally associated with increased bladder cancer risk. Similarly, elevated levels of phosphatidylcholine (16:0_22:6) and others were linked to increased kidney cancer risk. For prostate cancer, higher levels of SE (27:1/17:0) and others were associated with increased risk, while higher levels of SE (27:1/18:2) and others were associated with decreased risk. The study provides strong evidence for the causal relationships between plasma lipidome and bladder, kidney, and prostate cancers. These findings illuminate complex lipid metabolism pathways in urinary system cancer etiology and highlight specific lipid structures' differential impact on cancer risk. This research lays a foundation for further exploring biological mechanisms and developing early screening tools and targeted therapies for urological cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.